Blog
RSS FeedPosted by Michael Wonder on 18 Jun 2021
Efficient funding of chemotherapy review - submissions on discussion paper
18 June 2021 - The efficient funding of chemotherapy review discussion paper was released on 21 May 2021 to gain ...
Posted by Michael Wonder on 17 Jun 2021
Agenus announces U.S. FDA acceptance and priority review of balstilimab biologics license application for the treatment of recurrent or metastatic cervical cancer
17 June 2021 - Agenus today announced that the U.S. FDA has accepted Agenus’ biologics license application for balstilimab, an ...
Posted by Michael Wonder on 17 Jun 2021
Expanded PBS listing to save Australians around $120,000 a year
17 June 2021 - More than 800 Australians with stage IV advanced or metastatic kidney cancer will now have improved access ...
Posted by Michael Wonder on 16 Jun 2021
FDA approves avapritinib for advanced systemic mastocytosis
16 June 2021 - On June 16, 2021, the FDA approved avapritinib (Ayvakit, Blueprint Medicines) for adult patients with advanced ...
Posted by Michael Wonder on 16 Jun 2021
Novartis prostate cancer drug receives U.S. FDA breakthrough designation
17 June 2021 - Swiss drugmaker Novartis has received breakthrough therapy designation from the U.S. FDA for an experimental treatment ...
Posted by Michael Wonder on 15 Jun 2021
Istari Oncology announces FDA granted fast track designation to PVSRIPO for the treatment of advanced melanoma
14 June 2021 - Istari Oncology announced today the U.S. FDA has granted fast track designation to PVSRIPO for the ...
Posted by Michael Wonder on 14 Jun 2021
Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients
14 June 2021 - Bristol Myers Squibb’s immunotherapy combination Opdivo plus Yervoy has been recommended by NICE for the treatment ...
Posted by Michael Wonder on 14 Jun 2021
NICE to reassess Kyowa Kirin’s Poteligeo
14 June 2021 - NICE will reassess Kyowa Kirin’s rare blood cancer treatment Poteligeo after upholding an appeal launched by ...
Posted by Michael Wonder on 11 Jun 2021
Delytact oncolytic virus G47∆ approved in Japan for treatment of patients with malignant glioma
10 June 2021 - First oncolytic virus ever approved for treatment of malignant glioma or any primary brain cancer. ...
Posted by Michael Wonder on 10 Jun 2021
Core patient reported outcomes in cancer clinical trials
9 June 2021 - This guidance provides recommendations to sponsors for collection of a core set of patient reported clinical outcomes ...
Posted by Michael Wonder on 10 Jun 2021
Yuhan's Leclaza to be cheaper than AstraZeneca's Tagrisso
10 June 2021 - The price of Yuhan's third generation epidermal growth factor receptor tyrosine kinase inhibitor for treating patients ...
Posted by Michael Wonder on 10 Jun 2021
Astellas’ Xtandi bags NICE approval in prostate cancer
10 June 2021 - Astellas’ oral treatment Xtandi has received approval from NICE for the treatment of metastatic hormone-sensitive prostate ...
Posted by Michael Wonder on 10 Jun 2021
Copiktra (duvelisib) receives European Union marketing authorisation for the treatment of relapsed or refractory CLL and refractory FL
9 June 2021 - Secura Bio today announced that on 19 May 2021, the European Medicines Agency granted marketing authorisation for ...
Posted by Michael Wonder on 09 Jun 2021
BeiGene announces acceptance of a supplemental biologics license application in China for tislelizumab in microsatellite instability-high or mismatch repair-deficient solid tumours
7 June 2021 -BeiGene today announced that the Center for Drug Evaluation of the China NMPA has accepted a supplemental ...
Posted by Michael Wonder on 08 Jun 2021
Alpha Tau receives breakthrough device designation from the FDA for Alpha DaRT
8 June 2021 - Alpha Tau Medical is pleased to announce that it has received a breakthrough device designation for Alpha ...